Oxford BioDynamics (OBD) AI Stock Analysis

• Market Cap: £5.09M
• Dividend Yield: N/A
• Average Volume (3M): 10.18M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.54
• Revenue Growth: 45.22%
• EPS Growth: N/A
• Country: UK
• Employees: 51
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 1,957,577,600
• 10 Day Avg. Volume: 12,486,738
• 30 Day Avg. Volume: 10,177,963
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: 0.50p ▲(92.31%Upside)

Oxford BioDynamics' overall score is primarily impacted by its weak financial performance and negative technical indicators. Despite positive corporate events suggesting potential for future growth, the current financial and technical challenges weigh heavily on the stock's outlook.

Oxford BioDynamics Business Overview & Revenue Model

Company Description

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

How the Company Makes Money

Oxford BioDynamics (OBD) generates revenue through the sale of its EpiSwitch-based diagnostic tests to healthcare providers, laboratories, and research institutions. The company also engages in strategic partnerships and collaborations with pharmaceutical and biotechnology companies to leverage its epigenetic platform in drug development and clinical trials. Additionally, OBD may earn income through licensing agreements, where its proprietary technology is utilized by third parties for research and development purposes. These revenue streams are bolstered by the growing demand for precision medicine and personalized healthcare solutions.

Oxford BioDynamics Financial Statement Overview

Summary

Oxford BioDynamics faces substantial financial challenges with consistent net losses, rising leverage, and negative cash flows. Although there are some assets and equity, these are diminishing, indicating potential liquidity and solvency concerns.

Income Statement

Oxford BioDynamics shows a challenging financial trajectory with consistent net losses over the past years. The gross profit margin is low, and net income has been negative, indicating unprofitability. Revenue growth has been erratic, with no clear upward trend. EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet presents concerns, particularly in rising debt levels relative to equity, which has led to a rising debt-to-equity ratio. Return on equity is negative due to consistent net losses, and the equity ratio has decreased, indicating increased leverage and financial risk. However, there is still some equity cushion available, albeit shrinking.

Cash Flow

Cash flow analysis indicates significant strains with negative free cash flow and operating cash flow over the years. There was a notable decline in free cash flow growth rate, highlighting cash generation issues. Operating cash flow to net income ratio is negative, reinforcing operational cash challenges. Financing activities have been critical in supporting cash needs.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	617.00K	636.00K	510.00K	154.00K	341.00K	456.00K
Gross Profit	-7.49M	289.00K	266.00K	116.00K	-557.00K	-166.00K
EBITDA	-9.32M	-10.27M	-9.84M	-6.16M	-6.43M	-4.42M
Net Income	-11.11M	-11.57M	-10.83M	-6.71M	-6.68M	-4.31M
Balance Sheet
Total Assets	11.07M	12.11M	16.13M	11.34M	15.38M	15.35M
Cash, Cash Equivalents and Short-Term Investments	1.19M	2.83M	5.25M	999.00K	4.34M	11.51M
Total Debt	6.00M	5.74M	6.44M	6.14M	6.59M	541.00K
Total Liabilities	9.44M	7.75M	10.07M	8.76M	8.69M	1.77M
Stockholders Equity	1.62M	4.36M	6.05M	2.59M	6.68M	13.56M
Cash Flow
Free Cash Flow	-7.46M	-10.77M	-9.01M	-6.08M	-9.01M	-3.86M
Operating Cash Flow	-6.71M	-10.17M	-8.29M	-5.18M	-5.92M	-3.40M
Investing Cash Flow	1.68M	-1.49M	-691.00K	1.25M	2.83M	4.58M
Financing Cash Flow	5.03M	8.25M	13.42M	2.56M	-804.00K	-181.00K

Oxford BioDynamics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.38, and below the 200-day MA of 0.96, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 24.45 is Positive, neither overbought nor oversold. The STOCH value of 18.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBD.

Oxford BioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AREC	59 Neutral	£16.80M	―	-137.62%	―	10.50%	-9.60%
IXI	55 Neutral	£9.04M	―	-13.85%	―	7.27%	39.64%
APTA	54 Neutral	£7.47M	―	-99.43%	―	17.39%	96.02%
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
OBD	44 Neutral	£5.09M	―	-333.59%	―	45.22%	―
HEMO		£7.04M	―	-302.41%	―	―	―
FAB	44 Neutral	£7.33M	―	-129.49%	―	14.12%	78.16%

Oxford BioDynamics Corporate Events

Oxford BioDynamics Announces Changes in Major Holdings

Oxford BioDynamics PLC has announced a change in its major holdings, with Spreadex LTD acquiring or disposing of financial instruments, resulting in a shift in voting rights. This notification reflects a slight decrease in the total percentage of voting rights held by Spreadex, which may influence the company’s shareholder dynamics and strategic decisions moving forward.

Oxford BioDynamics Reports Strong Interim Results and Strategic Progress

Oxford BioDynamics Plc announced its interim results for the six-month period ending March 31, 2025, highlighting significant corporate and operational achievements. The company reported a substantial increase in revenue and cash reserves, driven by the growth in sales of its EpiSwitch PSE test and strategic agreements, such as the one with Bupa UK. Despite ongoing commercial discussions, no definitive deals have been secured, prompting the company to focus on preserving business integrity and optimizing shareholder value. The company also achieved ISO15189 accreditation for its UK lab and recorded its highest PSE sales in June 2025, indicating strong market acceptance and potential for future growth.

Oxford BioDynamics Sees Change in Financial Instrument Holdings

Oxford BioDynamics PLC has announced a change in its financial instrument holdings, as Spreadex LTD has adjusted its position in the company. The notification indicates that Spreadex now holds a total of 3.0049% of the voting rights in Oxford BioDynamics, reflecting a slight increase from its previous position. This adjustment may influence the company’s market dynamics and stakeholder interests as it continues to navigate the competitive landscape of the biotechnology sector.

Oxford BioDynamics’ Oxford Lab Achieves UKAS Accreditation for EpiSwitch® Tests

Oxford BioDynamics has announced that its Oxford-based laboratory has been accredited by the United Kingdom Accreditation Service (UKAS) under the ISO 15189 standard, allowing it to conduct EpiSwitch® Clinical Tests in the UK. This accreditation marks a significant milestone for the company, as it enhances the turnaround time for test results and supports the company’s strategy to centralize its clinical testing operations in the UK. The successful validation of the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) in the UK lab is expected to benefit cancer patients by reducing the time taken to receive test results, thereby strengthening the company’s position in the diagnostics industry and its relationship with partners like Bupa UK.

Oxford BioDynamics Director Increases Stake, Signaling Confidence

Oxford BioDynamics announced that Non-Executive Director Peter Presland has purchased 3,398,553 ordinary shares, representing approximately 0.17% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, highlights insider confidence in the company’s future prospects and could positively influence stakeholder perceptions and market positioning.